Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan

Robin L. Corelli (), Thanh G. Tu, Kyoung J. Lee, Drake Dinh, Kristin R. Gericke and Karen Suchanek Hudmon
Additional contact information
Robin L. Corelli: University of California-San Francisco School of Pharmacy
Thanh G. Tu: Cedars-Sinai Medical Center
Kyoung J. Lee: Hoag Memorial Hospital Presbyterian
Drake Dinh: MemorialCare Long Beach Medical Center
Kristin R. Gericke: University of California-San Francisco School of Pharmacy
Karen Suchanek Hudmon: University of California-San Francisco School of Pharmacy

PharmacoEconomics - Open, 2021, vol. 5, issue 4, No 8, 649-653

Abstract: Abstract Background Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. Objective The aim of this study was to characterize trends in smoking cessation medication utilization between 2006 and 2017 within a Medicaid population and estimate per-member per-month (PMPM) costs to the health plan. Methods This study was a retrospective longitudinal analysis conducted among adult members of a Medicaid managed care plan in California. Pharmacy claims data from January 1, 2006 to December 31, 2017 were analyzed to estimate utilization and cost of smoking cessation medications. Additionally, data from 3164 members who filled prescription(s) for cessation medication(s) in 2017 were evaluated to quantify quit attempts and use of combination therapy. For members who had been prescribed bupropion SR, varenicline, or the nicotine patch, the extent to which the durations of therapy were consistent with the manufacturers’ recommended minimum duration of therapy were also assessed. Results The average PMPM expenditures for smoking cessation medications were approximately US$0.15 in 2017, compared with US$0.01–US$0.03 between 2006 and 2013. In 2017, a total of 3164 members initiated an estimated 3850 quit attempts, most commonly using the nicotine patch (57.5%) or varenicline (32.8%). Combination therapy accounted for 2.9% of quit attempts. The median therapy duration for the nicotine patch, varenicline, and bupropion SR was 28, 30, and 33 days, respectively, and for each of these medications, fewer than half of members filled prescriptions for the minimum recommended duration of therapy. Conclusions Pharmacy claims data suggest that despite comprehensive coverage, most beneficiaries are underutilizing smoking cessation agents and are not completing the recommended treatment durations.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-021-00274-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:5:y:2021:i:4:d:10.1007_s41669-021-00274-7

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-021-00274-7

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().